Beck Mack & Oliver LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% during the first quarter, Holdings Channel reports. The fund owned 369,511 shares of the biopharmaceutical company’s stock after selling 2,339 shares during the quarter. Beck Mack & Oliver LLC’s holdings in Gilead Sciences were worth $24,022,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Athena Capital Advisors LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $27,000. Capital Financial Planning LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $27,000. Creative Financial Designs Inc. ADV lifted its holdings in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 165 shares during the period. Advisors Preferred LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $31,000. Finally, Legacy Financial Advisors Inc. lifted its holdings in shares of Gilead Sciences by 361.3% during the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 383 shares during the period. Institutional investors and hedge funds own 79.94% of the company’s stock.

In other news, Director John Francis Cogan sold 2,868 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $64.89, for a total value of $186,104.52. Following the completion of the transaction, the director now owns 57,728 shares in the company, valued at $3,745,969.92. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Gayle E. Wilson sold 19,068 shares of the firm’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $67.08, for a total value of $1,279,081.44. Following the completion of the transaction, the director now owns 143,567 shares of the company’s stock, valued at approximately $9,630,474.36. The disclosure for this sale can be found here. In the last three months, insiders sold 47,670 shares of company stock valued at $3,142,526. 0.20% of the stock is owned by corporate insiders.

Several brokerages recently weighed in on GILD. Mizuho set a $88.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, May 10th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a report on Tuesday, May 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a report on Monday, May 6th. Raymond James set a $83.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Friday, May 3rd. Finally, Cowen reaffirmed a “buy” rating on shares of Gilead Sciences in a report on Friday, May 3rd. Nine investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $81.61.

Gilead Sciences stock opened at $65.78 on Friday. Gilead Sciences, Inc. has a one year low of $60.32 and a one year high of $79.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The firm has a market capitalization of $81.81 billion, a price-to-earnings ratio of 10.70, a price-to-earnings-growth ratio of 0.78 and a beta of 1.14.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company had revenue of $5.28 billion during the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter last year, the company earned $1.48 earnings per share. Gilead Sciences’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, analysts predict that Gilead Sciences, Inc. will post 6.6 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.83%. The ex-dividend date of this dividend is Thursday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.

TRADEMARK VIOLATION WARNING: This piece was originally posted by Marea Informative and is owned by of Marea Informative. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.mareainformativa.com/news/2019/05/17/beck-mack-oliver-llc-lowers-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Story: What is the Bid-Ask Spread?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.